Rethinking Cancer

What RHCG, ammonia, and ancient nitrogen signaling reveal about the disease.

There is a protein family sitting in the membranes of organisms across the full span of life, from bacteria to fungi to plants to animals, that solves one of biology's oldest chemical problems: how to move ammonia across a lipid membrane without accidentally opening the door to potassium.

The family is called Amt/Mep/Rh: ammonium transporters, methylammonium permeases, and Rhesus glycoproteins. Bacteria use Amt proteins. Fungi and plants use Mep and AMT proteins. Animals use Rhesus glycoproteins, including RHCG, encoded by SLC42A3.

For a long time, this protein family could be treated as a simple story of direction: single-celled organisms use related transporters to acquire nitrogen. Multicellular animals use Rhesus glycoproteins to handle and excrete ammonia through epithelia such as kidney, intestine, gill, and other barrier tissues. That contrast is real, but it is not quite enough.

Cancer cells don't use a one-size-fits-all approach to ammonia export and RHCG activation; they dynamically adapt their pH-routing states to fit their local tissue environment. Sometimes that means RHCG-up. Sometimes that means RHCG-down. The invariant is not the direction of RHCG expression. The invariant is the disruption of the tissue's normal nitrogen and acid-base contract.

This post covers two interlocking ideas: the ancient chemistry of the Amt/Mep/Rh protein family, and the emerging view of ammonia in cancer not merely as toxic waste, but as a metabolic substrate, signaling molecule, pH stressor, and immune-modifying force. The important refinement is that cancer does not use RHCG in one universal direction. It chooses the state that makes local ammonia handling most advantageous.

Part I / The Blueprint

The Protein Family Evolution Kept

The Amt/Mep/Rh superfamily is one of the most conserved transporter families in biology. Its members are found across all three domains of life. The details differ by organism, tissue, and membrane polarity, but the underlying problem is the same: ammonia and ammonium are chemically useful, physiologically dangerous, and difficult to move selectively.

Human RHCG is a member of this family. Structural work on human RhCG shows a trimeric membrane complex with twelve transmembrane helices per monomer and a pore architecture suited to ammonia movement. When reconstituted into proteoliposomes, RhCG conducts NH₃ and can raise internal pH. In the kidney, RhBG and RhCG are not decorative blood-group leftovers; they are regulated epithelial ammonia transport proteins with major roles in acid-base homeostasis.

This matters because cancer is not inventing a new molecular system. It is altering the regulation and context of an old one.

The Potassium Mimicry Problem

Ammonium, NH₄⁺, and potassium, K⁺, are dangerously similar from the perspective of a membrane pore. They are both positively charged, and their hydrated behavior is close enough that a careless channel can confuse one for the other. But potassium is the dominant intracellular cation. It is central to membrane potential, electrochemical gradients, and the electrical logic of living cells.

            Why this matters: a channel that freely admits NH4+ can also threaten K+ homeostasis. That is not a small bookkeeping error. It can collapse the voltage system on which downstream signaling depends.
        

The Amt/Mep/Rh family solves this problem with a conserved pore logic built around two histidine residues in the channel lumen, often called the Twin-Histidine motif. The simplest way to describe the mechanism is this:

The Twin-Histidine Logic

Recruitment. NH₄⁺ reaches the mouth of the transporter.
Deprotonation. The protein environment favors conversion of charged NH₄⁺ into neutral NH₃ plus H⁺.
Selective transit. Neutral NH₃ can pass through the hydrophobic pore environment in a way charged ions cannot.
Reassociation. On the other side, NH₃ can take up a proton again and re-enter the local acid-base equilibrium.

Nitrogen isotope studies support ammonium deprotonation as a common transport feature across representative AMT-Mep-Rh proteins. Twin-His variant studies also show that disturbing this motif can shift the protein toward less specific ion-channel-like behavior and disrupt signaling in fungal Mep2 transceptors. In other words, the pore is not just a hole. Its chemistry is the point.

This is the first key idea: the protein family is ancient because the chemical problem is ancient. Ammonia is useful, toxic, diffusible, proton-sensitive, and tightly tied to pH. Life never escaped that problem. It learned to regulate it.

From Nitrogen Scavenging to Tissue Homeostasis

In microbes, ammonium transport is often part of nitrogen acquisition and growth control. Nitrogen is not waste in that context; it is food. Fungal Mep proteins are not only transporters but can act as transceptors, linking nitrogen availability to developmental programs such as filamentation.

In animals, the same chemical problem is embedded in a different body plan. A multicellular organism must protect shared extracellular spaces, blood chemistry, epithelial gradients, immune function, and organ-level acid-base balance. Ammonia ceased to function as a nutrient resource. It has to be routed, buffered, excreted, and compartmentalized.

Unicellular Logic

NITROGEN ACQUISITION

Ammonium is a biosynthetic resource.
Transport is linked to growth and nutrient signaling.
Local survival can override tissue-level restraint because there is no tissue.

Multicellular Logic

EPITHELIAL HOMEOSTASIS

Ammonia must be routed through organ-level clearance systems.
pH, ion gradients, immune function, and extracellular chemistry are shared goods.
Transport is valuable only when coordinated with the organism.

Evolution flipped the direction, functionally. The same conserved ammonia-handling machinery was placed under different regulatory contracts as life moved from single cells to tissues.

            The cancer-relevant implication: a tumor cell does not need to invent an ammonia program. It only needs to break the tissue-level contract controlling an ancient one.
        

Part II / RHCG As Routing Choice

RHCG Is Not a Universal Cancer Switch

A tempting model would make RHCG a simple hypoxia switch: chronic hypoxia stabilizes HIF-1α, HIF-1α remodels metabolism, glycolysis rises, mitochondrial oxidation falls, ammonia and protons accumulate, and RHCG is upregulated as a pressure-relief valve.

That pathway may be true in some epithelial stress settings. RHCG can be hypoxia-responsive; for example, hypoxic keratinocyte contexts outside cancer can induce RHCG expression. But the cancer literature does not support a universal "hypoxia means RHCG-up" rule. In several cancers, especially squamous epithelial cancers, the opposite pattern appears: RHCG is lost, suppressive, or epigenetically silenced.

This is not a problem for the thesis. It is the thesis becoming more precise.

            RHCG is not the invariant. The routing advantage is the invariant. In one tissue, RHCG-up may help maintain intracellular alkalinity, support migration, or move ammonia into a useful compartment. In another, RHCG-down may remove a normal epithelial ammonia-handling and tumor-suppressive program. Cancer selects the state that best fits the local ecology.
        

The RHCG-Down Branch

In esophageal squamous cell carcinoma (ESCC), RHCG was reported as downregulated while remaining expressed in multiple normal squamous epithelia. Later work strengthened this substantially: RHCG was frequently downregulated in ESCC, associated with poor differentiation, invasion, lymph node metastasis, and worse survival. Demethylation experiments and bisulfite analyses connected that loss to RHCG promoter hypermethylation. Functional restoration of RHCG reduced clonogenicity, motility, tumor formation, and metastasis.

Head and neck squamous cell carcinoma (HNSCC) shows a similar pattern. RHCG is downregulated in HNSCC tissues and cell lines, lower RHCG tracks with advanced stage and poor prognosis, and promoter hypermethylation is implicated in downregulation. Functional assays support RHCG as a suppressor of tumorigenicity and migration.

Cervical cancer adds another squamous-lineage example, though the mechanism should be phrased carefully. RHCG is downregulated in cervical cancer, and RHCG overexpression reduces proliferation and migration while increasing apoptosis. The available evidence supports "RHCG-down and tumor-suppressive" in cervical cancer, but does not establish RHCG promoter hypermethylation as the mechanism.

There is also a hypoxia bridge in ESCC that deserves careful wording. Hypoxia and HIF-1α can induce miR-10b-3p in ESCC. A separate ESCA/ESCC radiosensitivity study shows that miR-10b-3p directly targets RHCG, while circATIC can sponge miR-10b-3p, elevate RHCG, suppress progression, and improve radiosensitivity. This does not prove that hypoxia directly methylates RHCG. It does suggest that hypoxia may reinforce RHCG loss post-transcriptionally in at least one ESCC regulatory route.

Finally, RHCG promoter hypermethylation appears outside squamous cancers as well. In prostate cancer, RHCG promoter hypermethylation, paired with TCAF1, predicts biochemical recurrence after radical prostatectomy. That does not by itself prove an ammonia mechanism, but it does show that RHCG methylation is not a one-off oddity.

The RHCG-Up Branch

The opposite pattern also exists. In gastric cancer, high RHCG expression predicts poor survival and promotes migration, invasion, and proliferation. RHCG knockdown lowers intracellular pH and reduces malignant behavior. This is one of the cleanest examples of an RHCG-up state fitting the cancer advantage: the tumor appears to use RHCG to help keep the inside alkaline enough for growth and movement.

Endometrial cancer points the same way. RHCG is highly expressed, associated with clinical stage and tumor infiltrate, and RHCG knockdown reduces proliferation and migration while increasing apoptosis. In renal tumors, RHCG expression is lineage-specific: chromophobe renal cell carcinoma and renal oncocytoma express RHCG, whereas clear-cell and papillary renal cell carcinomas do not. That matters because it shows tissue origin and epithelial identity shape RHCG behavior.

RHCG State	Example Contexts	Likely Tumor Advantage	Evidence Strength
RHCG-up	Gastric cancer; endometrial cancer; chromophobe RCC / oncocytoma lineage	Intracellular alkalinity, growth, migration, invasion, lineage-fitted ammonia handling	Strong for gastric and endometrial cancer; lineage-specific for kidney tumors
RHCG-down or methylated	ESCC; HNSCC; cervical cancer; prostate cancer methylation marker	Loss of normal epithelial ammonia/pH handling; loss of RHCG-linked tumor-suppressive signaling; possible hypoxia-miRNA reinforcement in ESCC	Strong for ESCC and HNSCC; cervical downregulation strong, methylation unproven in this pass

Cancer does not choose RHCG expression in the abstract. It chooses the ammonia/pH-routing state that fits the tissue.

Part III / Ammonia As Architect

Ammonia in the Tumor: Waste, Nutrient, and Signal

The conventional framing treats ammonia in cancer as toxic metabolic waste. That is true, but incomplete. Ammonia can be toxic to cancer cells. It can destabilize genomes and impair lysosomal proteolysis. But in a tumor microenvironment where pH, glutamine metabolism, immune pressure, and nitrogen recycling are all altered, ammonia supports cancer growth.

The main source is glutaminolysis. Many cancer cells consume glutamine at high rates. Glutamine can be converted to glutamate, releasing ammonia, and glutamate can be further converted toward alpha-ketoglutarate through reactions that also intersect with ammonia production and nitrogen exchange. What should have been waste can become local chemistry.

The key is not that every tumor simply turns off detoxification. That would be too blunt. A better statement is that many tumors disable or reroute parts of organism-level nitrogen disposal. CPS1 can be silenced by DNA methylation in hepatocellular carcinoma. ASS1 deficiency can redirect aspartate and nitrogen flux toward pyrimidine synthesis. p53 can repress CPS1, OTC, and ARG1, increasing ammonia in ways that can also suppress polyamine biosynthesis and proliferation. The biology is not one-directional. It is routed.

That routing logic is exactly why ammonia belongs in the center of the cancer argument.

Five Ways Ammonia Rewrites the Tumor Environment

Signal 01

Recycled Nitrogen and Biomass

Ammonia is not always discarded. Breast cancer cells can recycle ammonia through glutamate dehydrogenase into amino acid metabolism, and tumors can use ammonia-derived nitrogen to support biomass. This turns a waste product into a local nitrogen source.

Signal 02

mTOR-Independent Autophagy

Glutaminolysis-derived ammonia can act as a diffusible autocrine and paracrine regulator of autophagy, independent of mTOR inhibition. That matters because autophagy is the cell's recycling system, and tumors under nutrient stress use recycling aggressively.

Signal 03

pH and Lysosomal Stress

NH₃ is the neutral fraction of total ammonia and can move across membranes. Once trapped in acidic compartments, it can alkalinize lysosomes and disrupt proteolysis. At the same time, extracellular acidity can protect cancer cells from ammonia toxicity. The result is a pH-dependent stress system, not a simple poison.

Signal 04

Nucleotide and Growth Routing

Urea-cycle lesions can redirect nitrogen-associated metabolites into proliferation. ASS1 deficiency, for example, can increase cytosolic aspartate availability and support pyrimidine synthesis through CAD activation and mTOR-linked signaling. This is not detox failure alone. It is growth rerouting.

Signal 05

Immune Suppression

In colorectal cancer, tumoral ammonia accumulation can reprogram T cells, increase exhaustion, reduce proliferation, and correlate with worse outcomes and poor checkpoint response. Enhancing ammonia clearance reactivates T cells and improves anti-PD-L1 efficacy in experimental models. Extracellular ammonia is therefore not inert background chemistry. It can shape immune failure.

            The tumor advantage is not "more ammonia" by itself. The advantage is controlled misrouting: enough ammonia to feed, signal, alkalinize, recycle, and suppress immunity, but not enough unbuffered toxicity to destroy the cancer cell first.
        

Part IV / Synthesis

Putting It Together: Not One Direction, One Selection Principle

RHCG sits at the junction of ammonia movement, epithelial pH handling, and ancient nitrogen-sensing biology. In normal tissue, that junction is governed by the organism. Kidney and other epithelia use RH glycoproteins to protect systemic acid-base balance and ammonia handling. In cancer, that governance is loosened, inverted, silenced, or exploited.

That is why RHCG can appear contradictory across tumors. In gastric cancer, RHCG-up helps keep the intracellular environment alkaline and supports malignant behavior. In endometrial cancer, RHCG-up also tracks with proliferation and migration. In ESCC and HNSCC, RHCG-down behaves like loss of a tumor suppressor, frequently tied to methylation and worse clinical features. In cervical cancer, RHCG-down is suppressor-like even though promoter methylation is not established as the mechanism. In prostate cancer, RHCG methylation carries prognostic value.

These are not separate stories. They are the same story expressed through different epithelial contexts.

Layer	Normal Tissue Logic	Cancer Logic
Transport	Regulated epithelial ammonia handling	Context-selected RHCG-up or RHCG-down routing
pH	Shared acid-base homeostasis	Local alkalinity/acidity tuned for tumor survival
Nitrogen	Disposal through coordinated urea-cycle and organ systems	Recycling into biomass or diversion into nucleotide synthesis
Stress response	Transient repair and recovery	Autophagy, hypoxia adaptation, and treatment resistance
Immunity	Immune recognition and clearance of abnormal cells	Ammonia-linked T-cell exhaustion and checkpoint resistance

The unifying feature is not one gene direction. It is the collapse of multicellular nitrogen governance into local tumor advantage.

A Convergent Picture

What emerges is more interesting than the original one-way model. Cancer is not simply reopening an ancient ammonia valve. It is editing the local rules of ammonia movement, pH control, nitrogen recycling, and immune pressure. RHCG is one of the clearest places where that edit becomes visible because the same protein can be advantageous in opposite directions depending on the tissue.

In one context, the tumor benefits from RHCG-up: ammonia movement and intracellular alkalinity support proliferation, migration, invasion, and treatment resistance. In another, the tumor benefits from RHCG-down: a normal epithelial ammonia-handling and tumor-suppressive program is removed, sometimes by promoter hypermethylation, sometimes by other regulatory routes, and possibly reinforced under hypoxia through miRNA pathways.

            The ancient blueprint is not merely being read. It is being re-routed.

            The cancer cell is not doing something wholly new. It is exploiting systems older than cancer itself: ammonia transport, nitrogen sensing, autophagy, pH compartmentalization, and immune evasion through metabolic stress. What changes is not the existence of those tools, but the level of organization they serve. In healthy tissue, they serve the organism. In cancer, they serve the local clone.

This redefines what is possible in treatment. The target is not RHCG alone, ammonia alone, hypoxia alone, or the urea cycle alone. The target is the misrouting network: transporter state, pH state, glutamine flux, GDH recycling, urea-cycle diversion, autophagy, and immune exhaustion. A tumor does not need all of these levers in the same direction. It needs the combination that works in its tissue.

That is why the bidirectional RHCG evidence matters. It prevents the argument from becoming a brittle rule. The stronger rule is evolutionary and ecological: cancer selects the nitrogen-handling state that breaks multicellular control most effectively in that context.

Research Blog - Terms of Use

Synergies for Cancer Treatment

Pages

Pages

Tuesday, June 16, 2026